<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367237</url>
  </required_header>
  <id_info>
    <org_study_id>P04422</org_study_id>
    <secondary_id>EUDRACT #: 2005-002189-12</secondary_id>
    <nct_id>NCT00367237</nct_id>
  </id_info>
  <brief_title>Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)</brief_title>
  <official_title>A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrated Therapeutics Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is undertaken to compare the efficacy and onset of action of infliximab plus
      methotrexate (IFX + MTX) versus methotrexate alone (MTX) in methotrexate naïve active
      psoriatic arthritis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16</measure>
    <time_frame>between baseline and week 16</time_frame>
    <description>&gt;=20% improvement in swollen and tender joint count AND &gt;=20% improvement in 3 of the following: visual analog scale (VAS) assessment of pain; subject VAS global assessment of disease activity; evaluator VAS global assessment of disease activity; Health Assessment Questionnaire (HAQ) disability index; C-Reactive Protein (CRP) level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving ACR50, ACR70, and PASI75 if Applicable</measure>
    <time_frame>between baseline and week 16</time_frame>
    <description>This is not a prespecified key secondary outcome; therefore, results will not be disclosed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score, Each of the ACR20 Domains, Dactylitis, Enthesitis, Fatigue and Duration of Morning Stiffness, Erythrocyte Sedimentation Rate, and Disability Index of the Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>between baseline and week 16</time_frame>
    <description>This is not a prespecified key secondary outcome; therefore, results will not be disclosed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>between baseline and week 16</time_frame>
    <description>This is not a prespecified key secondary outcome; therefore, results will not be disclosed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Arthritis, Psoriatic</condition>
  <arm_group>
    <arm_group_label>Infliximab + methotrexate (IFX + MTX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate (MTX)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral methotrexate (MTX) 15 mg/week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab + methotrexate (IFX + MTX)</intervention_name>
    <description>Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.</description>
    <arm_group_label>Infliximab + methotrexate (IFX + MTX)</arm_group_label>
    <other_name>Group 1, Remicade + MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (MTX)</intervention_name>
    <description>Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.</description>
    <arm_group_label>Methotrexate (MTX)</arm_group_label>
    <other_name>Group 2, MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must meet ALL of the criteria listed below for entry into the study:

          -  Subject must demonstrate their willingness to participate in the study and comply with
             its procedures by signing a written informed consent.

          -  Subject aged 18 years or more, of either sex and any race

          -  Diagnosis of Psoriatic Arthritis with peripheral polyarticular involvement. Patients
             will have at least one of the following:

               -  Distal Interphalangeal Joints (DIP) involvement

               -  polyarticular arthritis, absence of rheumatoid nodules and presence of psoriasis

               -  arthritis mutilans

               -  asymmetric peripheral arthritis

          -  Negative rheumatoid factor

          -  The disease should have been diagnosed at least 3 months prior to screening.

          -  Active disease at the time of screening and prior to receiving the baseline study
             medication(s) as defined by:

               -  5 or more swollen joints and

               -  5 or more tender joints

               -  and one out of the following three categories:

                    -  Erythrocyte Sedimentation Rate (ESR) &gt;= 28 mm/h

                    -  C-reactive protein (CRP) &gt;= 15 mg/l

                    -  Morning stiffness &gt;= 45 min

          -  Subjects must confirm that they are practicing adequate contraception: Female subjects
             of childbearing potential (includes women who are less than 1 year postmenopausal and
             women who become sexually active during the study) must agree to use a medically
             accepted method of contraception or be surgically sterilized prior to screening, while
             receiving protocol-specified medication, and for 6 months after stopping the
             medication. Acceptable methods of contraception include condoms (male and female) with
             or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically
             prescribed intrauterine device (IUD), oral or injectable hormonal contraceptive, and
             surgical sterilization (e.g., hysterectomy or tubal ligation).

          -  Female subjects of childbearing potential must have a negative pregnancy test at
             Screening.

          -  Subjects must be eligible for anti-tumor necrosis factor (TNF) treatment according to
             applicable local guidelines. For all patients chest X-ray and skin test results must
             be available at baseline.

          -  If using Nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids other than
             i.v., i.m. or i.a., the patient must be on a stable dose for four weeks prior
             screening (maximum dose up to 10mg/day of prednisone or its oral equivalent).

          -  The screening laboratory tests must beet the following criteria:

               -  Hemoglobin &gt;= 10 g/dl providing the low hemoglobin level is not due to other
                  diseases than anemia of chronic inflammation.

               -  white blood cell (WBC) &gt;= 3500 / μl

               -  Neutrophils &gt;= 1500 / μl

               -  Platelets &gt;= 100 000/ μl

               -  Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and
                  gamma-glutamyltransferase &lt;= 1.5 x upper limit of normal

               -  Total bilirubin &lt;= 1 x upper limit of normal

               -  Serum creatinine &lt;= 1.5 mg/dl

          -  Patient must be able to adhere to the study visit schedule and other protocol
             requirements and must have given informed consent prior to any screening procedures.

        Exclusion Criteria:

          -  The subject will be excluded from entry into the study if ANY of the criteria listed
             below are met:

          -  Subject is a female who is pregnant, intends to become pregnant during the study (or
             within 6 months after study completion), or nursing.

          -  Patients with other inflammatory diseases that might interfere with the evaluation of
             the psoriatic arthritis.

          -  Previous treatment with Infliximab.

          -  Subjects who have previously received MTX or have not discontinued their other DMARD
             therapy (i.e., sulfasalazine, hydroxychloroquine, leflunomide).

          -  Patients with fibromyalgia syndrome.

          -  Use of cyclosporine or tacrolimus within 4 weeks prior to screening. Use of IM, IV, or
             IA corticosteroids within 4 weeks prior to screening.

          -  Treatment with any investigational drug within 3 months prior to screening.

          -  Previous treatment with a monoclonal antibody or a fusion protein.

          -  A history of known allergy to murine proteins.

          -  History of infected joint prosthesis within the previous 5 years.

          -  Chronic infections.

          -  History of active tuberculosis requiring treatment within previous 3 years or history
             of opportunistic infections within 2 months, uncontrolled active infection or
             documented HIV infection. Also excluded are patients with evidence of latent
             tuberculosis and patients with old tuberculosis without documented adequate therapy,
             if they will not be treated according to local tuberculosis (TB) guidelines.

          -  Subject has any clinically significant deviation from normal in the physical
             examination, chest X-ray, or electrocardiogram (ECG) that, in the investigator's
             judgment, may interfere with the study evaluation or affect subject safety.

          -  Current signs or symptoms of other severe uncontrolled diseases, which in the
             investigators opinion would put the patient at an unacceptable risk.

          -  History of lymphoproliferative disease, any current malignancies or history of
             malignancy within 5 years other than successfully treated basal cell carcinoma or
             squamous cell carcinoma of the skin.

          -  Subject is part of the staff or a family member of the staff personnel directly
             involved with this study.

          -  History of drug abuse.

          -  Subjects who are participating in any other clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2006</study_first_posted>
  <results_first_submitted>March 19, 2009</results_first_submitted>
  <results_first_submitted_qc>May 21, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2009</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>115 subjects (57 infliximab (IFX) + MTX and 58 MTX), but only 110 subjects (56 and 54) were considered intent to treat (ITT). Furthermore, 99 subjects (51 + 48) were in a treatment group at Week 16 for Primary Endpoint evaluation.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Infliximab + Methotrexate (IFX + MTX)</title>
          <description>Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week</description>
        </group>
        <group group_id="P2">
          <title>Methotrexate (MTX)</title>
          <description>Oral methotrexate (MTX) 15 mg/week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57">Number of subjects randomized</participants>
                <participants group_id="P2" count="58">Number of subjects randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infliximab + Methotrexate (IFX + MTX)</title>
          <description>Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week</description>
        </group>
        <group group_id="B2">
          <title>Methotrexate (MTX)</title>
          <description>Oral methotrexate (MTX) 15 mg/week</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>ITT population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.1" lower_limit="20" upper_limit="65"/>
                    <measurement group_id="B2" value="42.3" lower_limit="21" upper_limit="65"/>
                    <measurement group_id="B3" value="41.2" lower_limit="20" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16</title>
        <description>&gt;=20% improvement in swollen and tender joint count AND &gt;=20% improvement in 3 of the following: visual analog scale (VAS) assessment of pain; subject VAS global assessment of disease activity; evaluator VAS global assessment of disease activity; Health Assessment Questionnaire (HAQ) disability index; C-Reactive Protein (CRP) level.</description>
        <time_frame>between baseline and week 16</time_frame>
        <population>Number of subjects from Intent-to-Treat population in each arm at Week 16</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab + Methotrexate (IFX + MTX)</title>
            <description>Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate (MTX)</title>
            <description>Oral methotrexate (MTX) 15 mg/week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16</title>
          <description>&gt;=20% improvement in swollen and tender joint count AND &gt;=20% improvement in 3 of the following: visual analog scale (VAS) assessment of pain; subject VAS global assessment of disease activity; evaluator VAS global assessment of disease activity; Health Assessment Questionnaire (HAQ) disability index; C-Reactive Protein (CRP) level.</description>
          <population>Number of subjects from Intent-to-Treat population in each arm at Week 16</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0210</p_value>
            <p_value_desc>Comparison of treatments (IFX + MTX versus MTX)</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in percentages of respondents</param_type>
            <param_value>19.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.27</ci_lower_limit>
            <ci_upper_limit>35.95</ci_upper_limit>
            <estimate_desc>Difference in percentages of respondents is (percentage of respondents in IFX+MTX group minus percentage of respondents in MTX group)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Proportion of Responders</param_type>
            <param_value>0.863</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Proportion of Responders</param_type>
            <param_value>0.667</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving ACR50, ACR70, and PASI75 if Applicable</title>
        <description>This is not a prespecified key secondary outcome; therefore, results will not be disclosed.</description>
        <time_frame>between baseline and week 16</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Disease Activity Score, Each of the ACR20 Domains, Dactylitis, Enthesitis, Fatigue and Duration of Morning Stiffness, Erythrocyte Sedimentation Rate, and Disability Index of the Health Assessment Questionnaire (HAQ)</title>
        <description>This is not a prespecified key secondary outcome; therefore, results will not be disclosed.</description>
        <time_frame>between baseline and week 16</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>This is not a prespecified key secondary outcome; therefore, results will not be disclosed.</description>
        <time_frame>between baseline and week 16</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety analyses included all subjects who received at least 1 dose of study medication
Subjects were questioned and/or examined by the investigator for evidence of adverse events. The questioning of subjects with regard to the possible occurrence of adverse events were to be generalized such as, “How have you been feeling since your last visit?”</desc>
      <group_list>
        <group group_id="E1">
          <title>Infliximab + Methotrexate (IFX + MTX)</title>
          <description>Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week</description>
        </group>
        <group group_id="E2">
          <title>Methotrexate (MTX)</title>
          <description>Oral methotrexate (MTX) 15 mg/week</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator must provide 30 days written notice to sponsor prior to submission for publication/presentation, so that sponsor can review the material(s). If the parties disagree concerning the appropriateness of the material for publication, the investigator must meet with sponsor prior to publication/presentation, in order to make good faith efforts to discuss and resolve any disagreements.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

